Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Fifth Consecutive Year

On July 27, 2022 Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, reported it has been named to the 2022 Disability Equality Index (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD) (Press release, Quest Diagnostics, JUL 27, 2022, View Source [SID1234617017]). The Disability Equality Index (DEI) is the world’s most comprehensive benchmarking tool for the Fortune 1000 to measure disability workplace inclusion against competitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to be named a ‘Best Place to Work for Disability Inclusion’ for the fifth consecutive year," said Cecilia McKenney, Quest’s Chief Human Resources Officer. "At Quest we are continuously working to create a diverse, equitable, inclusive, and accessible workplace where our employees can thrive in an environment that supports them."

As part of its commitment to empowering people with disabilities, Quest launched the DiverseAbilities Employee Business Network (EBN) in 2016, an open-door network of over 350 members. The vision of the group is to create and foster an inclusive culture of knowledge and dynamic acceptance of the disability community and support the company’s goal of becoming an Employer of Choice for the disability community. Earlier this year, the DiverseAbilities EBN launched the Cancer Awareness Connections sub-team to bring education and awareness that supports cancer patients, survivors, and caregivers. The DiverseAbilities EBN is one of 10 EBNs throughout Quest which are actively engaged in driving advocacy and influencing a culture of belonging.

"Quest is committed to building an inclusive culture that supports all employees," said Desyra Highsmith Holcomb, Director, Diversity & Inclusion at Quest Diagnostics. "We are proud of our EBNs and the supportive environments they create to help bring people together. The newly launched Cancer Awareness Connections sub-team is a great example of how our employees are connecting and supporting one another in meaningful ways."

The Disability Equality Index (DEI) is a comprehensive benchmarking tool that helps companies build a roadmap of measurable, tangible actions that they can take to achieve disability inclusion and equality. The DEI was created by the DEI Advisory Committee, a diverse group of business leaders, policy experts and disability advocates. Now in its eighth year, the DEI exists to help businesses make a positive impact on the unemployment/underemployment of people with disabilities.

This is the fifth consecutive year Quest has been recognized by the DEI, which is acknowledged as the most comprehensive benchmarking tool to measure disability workplace inclusion. The 2022 DEI measured: Culture & Leadership; Enterprise-Wide Access; Employment Practices (Benefits, Recruitment, Employment, Education, Retention & Advancement, Accommodations); Community Engagement; Supplier Diversity; Non-U.S. Operations.

"Disability inclusion is a rapidly expanding aspect of corporate culture, and it’s gratifying to partner with 415 companies on the 2022 Disability Equality Index," said Jill Houghton, President and CEO of Disability:IN. "These top-scoring companies not only excel in disability inclusion, many are also adopting emerging trends and pioneering measures that can move the disability agenda from accommodation to inclusion and ultimately, genuine belonging."

Read more about Quest’s award-winning culture on the company’s ESG Resources page. Find the full 2022 Disability Equality Index here.

PharmaMar Group reports results for the first half of 2022

On July 27, 2022 Pharma Mar Group (MSE: PHM) reported total revenues of €101.4 million at 30 June 2022, up 3% year-on-year. Of total revenues, recurring revenues (sales plus royalties) continued to grow due to the strong performance of the oncology business, rising 5% to €86.7m in the first half. Of these revenues, net sales of Yondelis totalled €35.9 million at 30 June (Press release, PharmaMar, JUL 27, 2022, View Sourcepharmamar-group-reports-results-for-the-first-half-of-2022/" target="_blank" title="View Sourcepharmamar-group-reports-results-for-the-first-half-of-2022/" rel="nofollow">View Source [SID1234617016]). It is important to note that gross sales of Yondelis grew 6% in the first six months of the year and that it was price pressure in Europe which brought net sales of Yondelis to the same level as in the first half of last year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sales of raw material to our partners, both for Yondelis and Zepzelca, increased notably in the first half of the year to €15.4 million, 54% more than in the same period of the previous year. This growth is mainly due to increased demand for Yondelis from Pharma Mar’s new partners in territories other than the US and Japan.

Zepzelca revenues from the early access programme in Europe totalled €11.1 million in the first six months of the year. This amount reflects the new law regulating in France the prices of drugs offered under the Temporary Authorisation for Use (ATU) system, which has led to significant discounts for those drugs.

This discount is the reason why, despite the increase in the number of patients treated with Zepzelca in the early access programme, revenues in the first half were below the €15.8 million of the first half of last year.

Royalty revenues totalled €21.5 million1 at 30 June, up 24% year-on-year.

Non-recurring revenues from licensing agreements amounted to €14.7 million at 30 June 2022 (€16.3 million at June 2021). This income corresponds to the recognition in revenues of the amounts received in 2020 as a result of the Zepzelca license agreement with Jazz Pharmaceuticals ($300 million), which are being recognized in the income statement based on the degree of progress with contractual commitments.

PharmaMar Group R&D investment in the first six months of the year increased by 39% to €40.3 million as a result of the progress in the various development areas, where, among other earlier trials, the company is currently conducting four Phase IIIs. Oncology is the area with the highest investment, with a total of €33.3 million euro, compared with €24.4 million in the same period of the previous year.

At 30 June, the PharmaMar Group generated €35.2 million in cash from operating activities. As a result, the Group’s cash and cash equivalents position increased to €251.5 million as of June 30 2022, compared with €212.6 million at the end of 2021. For its part, the company’s financial debt has been reduced by 10% compared to December 2021 and stands at €41.0 million, the Group’s lowest level of debt in more than 20 years. Thus, net cash has grown by 26% since the beginning of the year to €210.5 million.

As a result, PharmaMar Group obtained a net profit of €34.9 million in the first half.

Earnings videoconference call for analysts and investors

PharmaMar will host a videoconference for analysts and investors on Thursday 28 July 2022 at 13:00h (CET). The numbers to connect to the conference call are: +34 91 901 16 44 (from Spain), +1 646 664 1960 (from the US or Canada) or +44 20 3936 2999 (other countries). Participants’ access code: 307798

The videoconference and its recording can also be accessed via the following link: View Source on PharmaMar’s website, by visiting the Events Calendar section of the company’s website View Source

1 As our partner, Jazz Pharmaceuticals, has not yet reported its financial results for the first half of 2022, the royalties recorded in the first half of this year are an estimation based on our available information.

PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022

On July 27, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, reported that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022 (Press release, Perrigo Company, JUL 27, 2022, View Source,-2022 [SID1234617015]). The Company will also host a conference call beginning at 8:30 A.M. (EDT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at View Source or by phone at 888-317-6003, International 412-317-6061, and reference ID # 4031017. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EDT) Tuesday, August 9, until midnight Tuesday, August 16, 2022. To listen to the replay, dial 877-344-7529, International 412-317-0088, and use access code 3460338.

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

On July 27, 2022 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported that it will host a conference call and webcast on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2022 (Press release, Oncolytics Biotech, JUL 27, 2022, View Source [SID1234617014]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast

A webcast of the call will also be available on the Investor Relations page of Oncolytics’ website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 203-1112 (North America) or (647) 436-0148 (International) and using replay code: 8806-576#.

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

On July 27, 2022 NuCana plc (NASDAQ: NCNA), ("NuCana" or the "Company"), reported that it has received a written notification (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") and the matter is closed (Press release, Nucana BioPharmaceuticals, JUL 27, 2022, View Source [SID1234617013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As announced on June 3, 2022, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company’s American Depositary Shares (the "ADSs") had been below $1.00 for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, NuCana was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.

The Notification Letter confirmed that the Company evidenced a closing bid price of the Company’s ADSs on Nasdaq at or greater than the $1.00 per ADS minimum requirement for 10 consecutive business days from July 13, 2022 to July 26, 2022 and that the Company has regained compliance with the Minimum Bid Price Requirement.